Edgestream Partners L.P. Sells 815 Shares of Zoetis Inc. (NYSE:ZTS)

Edgestream Partners L.P. lessened its stake in Zoetis Inc. (NYSE:ZTS) by 7.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,820 shares of the company’s stock after selling 815 shares during the period. Edgestream Partners L.P.’s holdings in Zoetis were worth $1,600,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. State Street Corp raised its position in Zoetis by 0.5% during the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock valued at $3,864,488,000 after purchasing an additional 95,856 shares during the last quarter. Geode Capital Management LLC raised its position in Zoetis by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after purchasing an additional 185,364 shares during the last quarter. Bank of New York Mellon Corp raised its position in Zoetis by 8.5% during the 4th quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company’s stock valued at $906,202,000 after purchasing an additional 433,429 shares during the last quarter. Mizuho Securities USA LLC raised its position in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after purchasing an additional 4,829,815 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Zoetis by 5.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after purchasing an additional 194,542 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research report on Friday. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. Barclays increased their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and an average target price of $215.90.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by company insiders.

Zoetis Stock Performance

Zoetis stock opened at $171.70 on Tuesday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $76.89 billion, a P/E ratio of 31.39, a PEG ratio of 2.78 and a beta of 0.94. The stock’s 50 day moving average is $166.91 and its 200 day moving average is $176.66. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. Zoetis’s payout ratio is currently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.